<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04443049</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-32</org_study_id>
    <nct_id>NCT04443049</nct_id>
  </id_info>
  <brief_title>To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.</brief_title>
  <official_title>To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently the available first line palliative therapy for advanced HCC is Sorafenib and&#xD;
      Lenvatinib of which Lenvatinib is tolerated better. Unfortunately, patients tend to progress&#xD;
      after few months of therapy. Therefore it is imperative, to do trials by combinative therapy&#xD;
      to the available therapy for added survival benefits and quality of life with advanced HCC.&#xD;
      In this regard, Mebendazole appears to be a good choice for drug repurposing as it has shown&#xD;
      very promising results either alone or in combination with other therapies in tumors of GI&#xD;
      origin and CNS tumors. With regard to HCC Mebendazole has been found to be effective in vitro&#xD;
      system of HCC and preclinical models. However no clinical trials have been initiated till&#xD;
      now. The key hallmark features of HCC include activation of MAPK and angiogenesis which in&#xD;
      turn are targeted by RTK inhibitors such as Sorafenib and Lenvatinib. In this regard&#xD;
      Mebendazole has broad range of action by not only inhibiting angiogenesis and pro-survival&#xD;
      pathways of MAPK, but by also inhibiting the secretion of MMPs and Tubulin polymerization&#xD;
      which can all be beneficial in tumor regression and prevention of chemo-resistance in HCC.&#xD;
      Mounting of a strong immune response plays an important role in identification of tumor&#xD;
      antigen and thereby clearing of tumors. While Mebendazole can modulate the tumor, the data is&#xD;
      scant with respect to the role of the drug. Hence repurposing Mebendazole as a combinatorial&#xD;
      therapy appears a promising approach and forms the basis of the present work. We hypothesize&#xD;
      that combinatorial therapy of addition of mebendazole to lenvatinib will prove more&#xD;
      beneficial than lenvatinib alone in increasing the overall survival of patients with advanced&#xD;
      HCC. To prove the mechanistic effects of mebendazole on HCC, we will also conduct a animal&#xD;
      study in preclinical mice model of HCC with the help of our animal house facility. The animal&#xD;
      study will help us to understand the additional benefits from mebendazole and lenvatinib with&#xD;
      objective evidence of liver biopsy which is not feasible in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (A) STUDY HYPOTHESIS&#xD;
&#xD;
        -  Mebendazole augments response of lenvatinib by synergistic response.&#xD;
&#xD;
        -  Addition of anti angiogenic drugs (lenvatinib and mebendazole) to hypoxic environment&#xD;
           generated post locoregional therapy like TACE leads to more effective control of&#xD;
           advanced HCC resulting in improvement in overall survival.&#xD;
&#xD;
      (B) AIM: To compare the efficacy of combination of mebendazole with lenvatinib in cirrhotics&#xD;
      with advanced Hepatocellular Carcinoma.&#xD;
&#xD;
      (C) OBJECTIVE:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To compare the efficacy of combination of mebendazole with lenvatinib in improving the&#xD;
      overall survival at 15 months in cirrhotics with advanced HCC.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
        1. To compare the progression free survival with combination therapy of mebendazole and&#xD;
           lenvatinib in advanced Hepatocellular Carcinoma (HCC).&#xD;
&#xD;
        2. To compare the objective response rate (ORR), disease control rate (DCR) and clinical&#xD;
           benefit rate (CBR) with combinative therapy of mebendazole and lenvatinib in advanced&#xD;
           HCC.&#xD;
&#xD;
        3. To study therapy related adverse effects of mebendazole in cirrhotics.&#xD;
&#xD;
        4. To develop pre-clinical HCC animal model to prove the added efficacy of combination&#xD;
           therapy.&#xD;
&#xD;
      (D)STUDY DESIGN Type of study - Single center, prospective, open label, randomized control&#xD;
      study Study population - cirrhosis of liver of any etiology with advanced HCC undergoing at&#xD;
      ILBS Study duration - 22 months from the date of approval of IEC Sample size - Considering&#xD;
      mebendazole adds 2 months more to lenvatinib which offers 13 months overall survival, power&#xD;
      of the study as 80 %, attrition rate as 30 %, alpha error of 5%, sample size will be 85&#xD;
      patients in each arm ( totally 170 patients).&#xD;
&#xD;
      (F) Methodology: Cirrhotics with advanced HCC proven by imaging and or biopsy or cytology,&#xD;
      fulfilling the eligibility criteria will be enrolled in the study. They may undergo 1 or 2&#xD;
      sessions of locoregional therapy (TACE/ SBRT/RFA) if feasible. All patients will undergo&#xD;
      complete physical examination, CBC, LFT, KFT, INR, AFP, PIVKAII, CEMRI/ CECT upper abdomen&#xD;
      (Triple phase ), UGI endoscopy at baseline before randomization.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      Those patients who are not feasible for locoregional therapy will be randomized at baseline.&#xD;
      Those patients undergoing locoregional therapy will be randomized after 1 month of last&#xD;
      locoregional therapy (patient may undergo maximum of two sessions of locoregional therapy&#xD;
      before randomization). The response will be determined by m RECIST criteria before&#xD;
      randomization. Those patients requiring further sessions of locoregional therapy beyond two&#xD;
      sessions will not be randomized into study.&#xD;
&#xD;
      Patient will be then randomized to one of the two groups Arm I :Lenvatinib +Placebo(&#xD;
      Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is &lt; 60 kg and&#xD;
      12 mg if body weight is &gt; 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily&#xD;
      Arm II : Lenvatinib and mebendazole ( Lenvatinib will be given orally once a day (OD) at dose&#xD;
      of 8 mg if body weight is &lt; 60 kg and 12 mg if body weight is &gt; 60 kg) and mebendazole will&#xD;
      be given at dose of 100 mg orally twice a day (BD) daily&#xD;
&#xD;
      Follow-up Patients will be followed up with clinical events, CBC, LFT, KFT, INR, AFP,&#xD;
      PIVKAII, CEMRI/ CECT upper abdomen (Triple phase ) at the end of 1 month, 3 months, 6 months,&#xD;
      9 months, 12 months and 15 months.&#xD;
&#xD;
      INVESTIGATIONS AND FOLLOW UP At Baseline (before therapy) and during follow up&#xD;
&#xD;
        -  Hematology- repeated at the end of 1, 3, 6, 9, 12, 15 months.&#xD;
&#xD;
           - CBC&#xD;
&#xD;
        -  Biochemistry - repeated at the end of 1, 3, 6, 9, 12, 15 months.&#xD;
&#xD;
             -  Serum Electrolytes, Kidney function test&#xD;
&#xD;
             -  Liver function test, INR&#xD;
&#xD;
        -  CTP and MELD scores&#xD;
&#xD;
        -  AFP, PIVKA II - repeated at the end of 1, 3, 6, 9, 12, 15 months.&#xD;
&#xD;
        -  UGIE at baseline&#xD;
&#xD;
        -  CEMRI / CECT upper abdomen - Triple phase - repeated at the end of 1, 3, 6, 9, 12, 15&#xD;
           months.&#xD;
&#xD;
        -  PET CT - if systemic spread suspected or else at the end of 6 and 15 months&#xD;
&#xD;
        -  Liver Biopsy/FNAC will be done in cases where its clinically indicated.&#xD;
&#xD;
      The pre-clinical model will be developed in mice, for which separate application will be&#xD;
      submitted to the animal ethics committee of the institute.&#xD;
&#xD;
      Timeline of follow up&#xD;
&#xD;
        -  At the end of first month&#xD;
&#xD;
        -  Then every 3 months until 15 months after starting therapy&#xD;
&#xD;
      STATISTICAL ANALYSIS&#xD;
&#xD;
        -  Data will be reported as mean + SD&#xD;
&#xD;
        -  Categorical variables will be compared using the chi-square test or Fisher exact test&#xD;
&#xD;
        -  Normal continuous variables will be compared using the Student t test&#xD;
&#xD;
        -  Non normal continuous variables will be compared using the Mann-Whitney rank-sum test&#xD;
           (unpaired data) or the Wilcoxon test (paired data).&#xD;
&#xD;
        -  Comparison between groups on quantitative variables will be analyzed by ANOVA&#xD;
&#xD;
        -  The actuarial probability of survival will be calculated by the Kaplan-Meier method and&#xD;
           compared using the log-rank test&#xD;
&#xD;
        -  A Cox regression analysis will be performed to identify independent prognostic factors&#xD;
           for survival.&#xD;
&#xD;
      Intervention: This Randomized Controlled trial will be conducted at Institute of Liver &amp;&#xD;
      Biliary SciencesLBS New Delhi between June 2020 and March 2022&#xD;
&#xD;
      Salvage therapy&#xD;
&#xD;
        -  TACE or TARE if progressive disease&#xD;
&#xD;
        -  Nivolilumab if the patient had a progressive disease at 6 months of therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2020</start_date>
  <completion_date type="Anticipated">June 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival in both groups</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progressive disease requiring change of therapy in both groups</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive disease requiring quitting therapy in both groups</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy related adverse effects in both groups</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening of performance status in both groups</measure>
    <time_frame>2 year</time_frame>
    <description>Worsening of performance will be measured by Eastern Cooperative Oncology Group (ECOG) Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decompensation of underlying cirrhosis in both groups</measure>
    <time_frame>2 year</time_frame>
    <description>Barcelona-Clinic Liver Cancer (BCLC) staging classification will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Lenvatinib +Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is &lt; 60 kg and 12 mg if body weight is &gt; 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenvatinib and mebendazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is &lt; 60 kg and 12 mg if body weight is &gt; 60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is &lt; 60 kg and 12 mg if body weight is &gt; 60 kg</description>
    <arm_group_label>Lenvatinib +Placebo</arm_group_label>
    <arm_group_label>Lenvatinib and mebendazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mebendazole</intervention_name>
    <description>mebendazole will be given at dose of 100 mg orally twice a day (BD) daily</description>
    <arm_group_label>Lenvatinib and mebendazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Tab Mecovit) orally twice a day (BD) daily</description>
    <arm_group_label>Lenvatinib +Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis of Liver with HCC on imaging and/or biopsy or cytology&#xD;
&#xD;
          -  Child Pugh A, Child Pugh B &lt; 8&#xD;
&#xD;
          -  Advanced HCC - as defined by BCLC - C&#xD;
&#xD;
          -  ECOG Performance Status 1-2&#xD;
&#xD;
          -  Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents,&#xD;
             defined as BP ≤150/90 millimeters of mercury (mmHg) at screening and no change in&#xD;
             antihypertensive therapy within 1 week prior to commencement of intervention.&#xD;
&#xD;
          -  Valid Consent&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decompensated Cirrhosis&#xD;
&#xD;
          -  Child Pugh C, Child Pugh B &gt; 7&#xD;
&#xD;
          -  HCC patients with a curative therapy (RFA/MWA or LT)&#xD;
&#xD;
          -  Prior systemic therapies (or) immunotherapy for HCC&#xD;
&#xD;
          -  ECOG Performance Status 3-4&#xD;
&#xD;
          -  Post Liver transplant HCC recurrence&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Navin Kumar, MD</last_name>
    <phone>01146300000</phone>
    <email>navinktanvi10@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Naveen Kumar, MD</last_name>
      <phone>01146300000</phone>
      <email>navinktanvi10@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mebendazole</mesh_term>
    <mesh_term>Piperazine</mesh_term>
    <mesh_term>Piperazine citrate</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>DMP 777</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04443049
org study id: ILBS-Cirrhosis-32
nct id: NCT04443049
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Currently the available first line palliative therapy for advanced HCC is Sorafenib and
      Lenvatinib of which Lenvatinib is tolerated better. Unfortunately, patients tend to progress
      after few months of therapy. Therefore it is imperative, to do trials by combinative therapy
      to the available therapy for added survival benefits and quality of life with advanced HCC.
      In this regard, Mebendazole appears to be a good choice for drug repurposing as it has shown
      very promising results either alone or in combination with other therapies in tumors of GI
      origin and CNS tumors. With regard to HCC Mebendazole has been found to be effective in vitro
      system of HCC and preclinical models. However no clinical trials have been initiated till
      now. The key hallmark features of HCC include activation of MAPK and angiogenesis which in
      turn are targeted by RTK inhibitors such as Sorafenib and Lenvatinib. In this regard
      Mebendazole has broad range of action by not only inhibiting angiogenesis and pro-survival
      pathways of MAPK, but by also inhibiting the secretion of MMPs and Tubulin polymerization
      which can all be beneficial in tumor regression and prevention of chemo-resistance in HCC.
      Mounting of a strong immune response plays an important role in identification of tumor
      antigen and thereby clearing of tumors. While Mebendazole can modulate the tumor, the data is
      scant with respect to the role of the drug. Hence repurposing Mebendazole as a combinatorial
      therapy appears a promising approach and forms the basis of the present work. We hypothesize
      that combinatorial therapy of addition of mebendazole to lenvatinib will prove more
      beneficial than lenvatinib alone in increasing the overall survival of patients with advanced
      HCC. To prove the mechanistic effects of mebendazole on HCC, we will also conduct a animal
      study in preclinical mice model of HCC with the help of our animal house facility. The animal
      study will help us to understand the additional benefits from mebendazole and lenvatinib with
      objective evidence of liver biopsy which is not feasible in humans.
(A) STUDY HYPOTHESIS

        -  Mebendazole augments response of lenvatinib by synergistic response.

        -  Addition of anti angiogenic drugs (lenvatinib and mebendazole) to hypoxic environment
           generated post locoregional therapy like TACE leads to more effective control of
           advanced HCC resulting in improvement in overall survival.

      (B) AIM: To compare the efficacy of combination of mebendazole with lenvatinib in cirrhotics
      with advanced Hepatocellular Carcinoma.

      (C) OBJECTIVE:

      Primary objective:

      To compare the efficacy of combination of mebendazole with lenvatinib in improving the
      overall survival at 15 months in cirrhotics with advanced HCC.

      Secondary objective:

        1. To compare the progression free survival with combination therapy of mebendazole and
           lenvatinib in advanced Hepatocellular Carcinoma (HCC).

        2. To compare the objective response rate (ORR), disease control rate (DCR) and clinical
           benefit rate (CBR) with combinative therapy of mebendazole and lenvatinib in advanced
           HCC.

        3. To study therapy related adverse effects of mebendazole in cirrhotics.

        4. To develop pre-clinical HCC animal model to prove the added efficacy of combination
           therapy.

      (D)STUDY DESIGN Type of study - Single center, prospective, open label, randomized control
      study Study population - cirrhosis of liver of any etiology with advanced HCC undergoing at
      ILBS Study duration - 22 months from the date of approval of IEC Sample size - Considering
      mebendazole adds 2 months more to lenvatinib which offers 13 months overall survival, power
      of the study as 80 %, attrition rate as 30 %, alpha error of 5%, sample size will be 85
      patients in each arm ( totally 170 patients).

      (F) Methodology: Cirrhotics with advanced HCC proven by imaging and or biopsy or cytology,
      fulfilling the eligibility criteria will be enrolled in the study. They may undergo 1 or 2
      sessions of locoregional therapy (TACE/ SBRT/RFA) if feasible. All patients will undergo
      complete physical examination, CBC, LFT, KFT, INR, AFP, PIVKAII, CEMRI/ CECT upper abdomen
      (Triple phase ), UGI endoscopy at baseline before randomization.

      Randomization:

      Those patients who are not feasible for locoregional therapy will be randomized at baseline.
      Those patients undergoing locoregional therapy will be randomized after 1 month of last
      locoregional therapy (patient may undergo maximum of two sessions of locoregional therapy
      before randomization). The response will be determined by m RECIST criteria before
      randomization. Those patients requiring further sessions of locoregional therapy beyond two
      sessions will not be randomized into study.

      Patient will be then randomized to one of the two groups Arm I :Lenvatinib +Placebo(
      Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and
      12 mg if body weight is > 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily
      Arm II : Lenvatinib and mebendazole ( Lenvatinib will be given orally once a day (OD) at dose
      of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg) and mebendazole will
      be given at dose of 100 mg orally twice a day (BD) daily

      Follow-up Patients will be followed up with clinical events, CBC, LFT, KFT, INR, AFP,
      PIVKAII, CEMRI/ CECT upper abdomen (Triple phase ) at the end of 1 month, 3 months, 6 months,
      9 months, 12 months and 15 months.

      INVESTIGATIONS AND FOLLOW UP At Baseline (before therapy) and during follow up

        -  Hematology- repeated at the end of 1, 3, 6, 9, 12, 15 months.

           - CBC

        -  Biochemistry - repeated at the end of 1, 3, 6, 9, 12, 15 months.

             -  Serum Electrolytes, Kidney function test

             -  Liver function test, INR

        -  CTP and MELD scores

        -  AFP, PIVKA II - repeated at the end of 1, 3, 6, 9, 12, 15 months.

        -  UGIE at baseline

        -  CEMRI / CECT upper abdomen - Triple phase - repeated at the end of 1, 3, 6, 9, 12, 15
           months.

        -  PET CT - if systemic spread suspected or else at the end of 6 and 15 months

        -  Liver Biopsy/FNAC will be done in cases where its clinically indicated.

      The pre-clinical model will be developed in mice, for which separate application will be
      submitted to the animal ethics committee of the institute.

      Timeline of follow up

        -  At the end of first month

        -  Then every 3 months until 15 months after starting therapy

      STATISTICAL ANALYSIS

        -  Data will be reported as mean + SD

        -  Categorical variables will be compared using the chi-square test or Fisher exact test

        -  Normal continuous variables will be compared using the Student t test

        -  Non normal continuous variables will be compared using the Mann-Whitney rank-sum test
           (unpaired data) or the Wilcoxon test (paired data).

        -  Comparison between groups on quantitative variables will be analyzed by ANOVA

        -  The actuarial probability of survival will be calculated by the Kaplan-Meier method and
           compared using the log-rank test

        -  A Cox regression analysis will be performed to identify independent prognostic factors
           for survival.

      Intervention: This Randomized Controlled trial will be conducted at Institute of Liver &
      Biliary SciencesLBS New Delhi between June 2020 and March 2022

      Salvage therapy

        -  TACE or TARE if progressive disease

        -  Nivolilumab if the patient had a progressive disease at 6 months of therapy
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Overall survival in both groups
time frame: 15 months
measure: Death
time frame: 2 year
measure: Progressive disease requiring change of therapy in both groups
time frame: 2 year
measure: Progressive disease requiring quitting therapy in both groups
time frame: 2 year
measure: Therapy related adverse effects in both groups
time frame: 2 year
measure: Worsening of performance status in both groups
time frame: 2 year
description: Worsening of performance will be measured by Eastern Cooperative Oncology Group (ECOG) Criteria.
measure: Decompensation of underlying cirrhosis in both groups
time frame: 2 year
description: Barcelona-Clinic Liver Cancer (BCLC) staging classification will be used.
arm group label: Lenvatinib +Placebo
arm group type: Active Comparator
description: Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg ) with placebo (Tab Mecovit) orally twice a day (BD) daily
arm group label: Lenvatinib and mebendazole
arm group type: Experimental
description: Lenvatinib will be given orally once a day (OD) at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg) and mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
intervention type: Drug
intervention name: Lenvatinib
description: Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is < 60 kg and 12 mg if body weight is > 60 kg
arm group label: Lenvatinib +Placebo
arm group label: Lenvatinib and mebendazole
intervention type: Drug
intervention name: Mebendazole
description: mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
arm group label: Lenvatinib and mebendazole
intervention type: Other
intervention name: Placebo
description: Placebo (Tab Mecovit) orally twice a day (BD) daily
arm group label: Lenvatinib +Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
last name: Dr Navin Kumar, MD
phone: 01146300000
email: navinktanvi10@gmail.com
facility: 
status: Recruiting
contact: 
country: India
responsible party type: Sponsor
mesh term: Carcinoma
mesh term: Carcinoma, Hepatocellular
mesh term: Liver Cirrhosis
mesh term: Mebendazole
mesh term: Piperazine
mesh term: Piperazine citrate
mesh term: Lenvatinib
mesh term: DMP 777
sharing ipd: Undecided